Hospital laboratory directors, procurement teams, and public health agencies form the demand base for klebsiella testing, buying tools to support antimicrobial-resistance surveillance. What they purchase spans culture-based identification, molecular and immunoassay-based detection, and imaging used to support a clinical diagnosis, all aimed at confirming Klebsiella pneumoniae infection, guiding antibiotic choice, and tracking resistant strains. Contrive Datum Insights lays out this buying pattern in its report titled "Klebsiella Testing Market Size, Share & Industry Analysis, By Type (Laboratory Test, Imaging Test, Other), Application (Laboratory Test, Imaging Test, Other), Technology (Culture-Based Testing, Molecular Diagnostics, Immunoassay-Based Testing, MALDI-TOF Mass Spectrometry, Other), End user (Hospital Laboratories, Diagnostic & Reference Laboratories, Academic & Research Institutes, Other), Sample type (Respiratory, Blood, Urine, Other), and Regional Forecast, 2026-2034."
Where the Spending Goes
Buyers spent USD 270 million on klebsiella testing in 2025. That figure rises to USD 302 million in 2026 and to USD 731 million by 2034, a compound annual growth rate of 11.68% for the forecast period.
Laboratory testing draws the largest share of that spending, USD 210.6 million, 78% of 2025 revenue; the application axis shows the same 78% share. Its dollar total keeps climbing through 2034, but its own 11.03% growth rate sits below the market's, so its share of the total eases to 74%. Purchases are shifting fastest toward the Other type line, which grows at 15.71% a year, moving from USD 35.1 million to USD 131.58 million and lifting its share of type revenue from 13% to 18%; the same category in the application axis grows at 15.81%. Culture-based platforms still capture the largest slice of technology spending, 42% of 2025 revenue at USD 113.4 million, while buyers are adding molecular diagnostics fastest, at 14.87% annually. Hospital laboratories remain the single largest end-user group, 46% of 2025 revenue at USD 124.2 million, though academic and research institutes are increasing their purchases quicker, at 12.56%. By sample type, respiratory specimens lead with 38% of 2025 revenue (USD 102.6 million); the Other sample category is growing fastest, at 12.89%.
North America holds 38% of 2025 revenue, USD 102.6 million, and stays the largest region as its total climbs to USD 248.54 million by 2034. Asia Pacific closes part of that gap over the same period: its share moves from 24% to 30% as revenue grows from USD 64.8 million to USD 219.3 million. The Middle East and Africa stays smallest throughout, edging up from 5% to 5.5%. Inside North America, the United States alone accounts for USD 87.21 million of 2025 revenue, 32.3% of the global total, the largest of any single country tracked in the report.
Rising rates of antimicrobial-resistant Klebsiella infection are pushing resistance testing into standard practice, the strongest single driver of growth in the study. If molecular and point-of-care platforms spread through hospital laboratories faster than expected, and public funding for resistance surveillance expands with them, 2034 revenue could reach USD 818.72 million. A slower path exists too: tighter budgets in public health laboratories and continued reliance on culture-based methods would hold 2034 revenue near USD 657.9 million. Either scenario leaves the underlying buyer base intact; what changes is how quickly hospital and reference laboratories replace older methods with newer ones.
The report breaks the market into five segments (type, application, technology, end user, and sample type) with revenue and growth figures for each line from 2020 through 2034, plus bear, base, and bull scenarios for the 2034 total. Coverage extends to all five regions with country-level detail, the competitive landscape, and the methodology behind each estimate. It is delivered as a PDF, and a free sample is available on request.